Effect of gamma-oryzanol as therapeutic agent to prevent cardiorenal metabolic syndrome in animals submitted to high sugar-fat diet

• Autor(a) principal: Francisqueti, Fabiane Valentini [UNESP]
• Data de Publicação: 2017
• Outros Autores: Minatel, Igor Otávio [UNESP], Ferron, Artur Junio Togneri [UNESP], Bazan, Silméia Garcia Zanati [UNESP], Silva, Vanessa dos Santos [UNESP], Garcia, Jéssica Leite [UNESP], de Campos, Dijon Henrique Salomé [UNESP], Ferreira, Ana Lúcia [UNESP], Moreto, Fernando [UNESP], Cicogna, Antonio Carlos [UNESP], Corrêa, Camila Renata [UNESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.3390/nu9121299; http://hdl.handle.net/11449/179412
• topic: Cardiac dysfunction; Cardiorenal Metabolic Syndrome; Gamma-oryzanol; High sugar-fat diet; Obesity; Renal disease

Background: The high consumption of fat and sugar contributes to the development of obesity and co-morbidities, such as diabetes, and cardiovascular and kidney diseases. Different strategies have been used to prevent these diseases associated with obesity, such as changes in eating habits and/or the addition of dietary components with anti-inflammatory and anti-oxidant properties, such as gamma-oryzanol (γQz) present mainly in bran layers and rice germ. Methods: Animals were randomly divided into four experimental groups and fed ad libitum for 20 weeks with control diet (C, n = 8), control diet + γOz (C + yOz, n = 8), high-sugar and high-fat diet (HSF, n = 8), and high-sugar and high-fat diet + γOz (HSF + γOz, n = 8). HSF groups also received water + sucrose (25%). The dose of γOz was added to diets to reach 0.5% of final concentration (w/w). Evaluation in animals included food and caloric intake, body weight, plasma glucose, insulin, triglycerides, uric acid, HOMA-IR, glomerular filtration rate, protein/creatinine ratio, systolic blood pressure, and Doppler echocardiographic. Results: Animals that consumed the HSF diet had weight gain compared to group C, increased insulin, HOMA, glucose and triglycerides, there were also atrial and ventricular structural alterations, deterioration of systolic and diastolic function, decreased glomerular filtration rate, and proteinuria. Gamma-oryzanol is significantly protective against effects on body weight, hypertriglyceridemia, renal damage, and against structural and functional alteration of the heart. Conclusion: Gamma-oryzanol shows potential as a therapeutic to prevent Cardiorenal Metabolic Syndrome.